Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...

Hyundai will offer a hybrid version of the newly redesigned Palisade in South Korea; we could well see that variant offered ...

Greetings and welcome to Chimera Investment Corporation fourth quarter and full year 2024 earnings conference call. At this time, all participants are in a listen-only mode. A question-and-answer ...

The Korea-spec version of the new three-row SUV comes with a 281-hp turbo-four as standard, and the hybrid version of that ...

The V6 provides extra oomph most four-cylinder engines can't manage, and today's V6 is more efficient than those of ...

Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure ...

Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...

Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without ...

The exhibition at Fondazione Giorgio Cini will showcase the details and design of the future Fondation Cartier’s space at ...

Data presented at the 2025 Crohn's and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company ...

Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.